No products in the cart.
Pre-made Elezanumab benchmark antibody ( Whole mAb, anti-RGMA therapeutic antibody, Anti-RGM Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-169
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Elezanumab biosimilar, Whole mAb, Anti-RGMA Antibody: Anti-RGM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke.
| Products Name (INN Index) | Pre-Made Elezanumab biosimilar, Whole mAb, Anti-RGMA Antibody: Anti-RGM therapeutic antibody |
|---|---|
| INN Name | Elezanumab |
| Target | RGMA |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | AbbVie |
| Conditions Approved | NA |
| Conditions Active | Multiple sclerosis,Spinal cord injuries,Stroke |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | RGMA |
| Package |
Previous slide
Next slide
